Atossa Therapeutics (ATOS)

• Market cap: $80.5M
• 1 day: 2.99%
• 5 days: 5.66%
• 1 month: -14.67%
• 3 months: -24.54%
• 6 months: -57.03%
• Year to date: -35.10%
• 1 year: -53.84%
• 5 years: -69.90%
• 10 years: -99.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Employees: 13

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

59% more call options, than puts

Call options by funds: $165K | Put options by funds: $104K

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

2.05% more ownership

Funds ownership: 21.74% [Q3] → 23.79% (+2.05%) [Q4]

0% more funds holding

Funds holding: 86 [Q3] → 86 (+0) [Q4]

32% less capital invested

Capital invested by funds: $41.6M [Q3] → $28.3M (-$13.3M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 1,023% upside
• Avg. target: $7 1,023% upside
• High target: $7 1,023% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 11% 1-year accuracy 18 / 159 met price target

1,023% upside $7

Buy Reiterated

26 Mar 2025